Pharmaceuticals, Biotechnology and Life Sciences
ROCKVILLE, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company…
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative…
Veteran executive brings more than 30 years of biopharmaceutical public relations and public affairs experienceFLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE…
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its…
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…
SANTA CLARA, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and…
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing…
Estimated 28% reduction in annual operating expenses for 2023 compared to previously announced guidance for 2022 of $162-167 million;Estimated total…
– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from…